We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus

By LabMedica International staff writers
Posted on 29 Dec 2023
Print article
Image: Bruker has made two year-end acquisitions of ELITechGroup and Phasefocus (Photo courtesy of Bruker)
Image: Bruker has made two year-end acquisitions of ELITechGroup and Phasefocus (Photo courtesy of Bruker)

Bruker Corporation (Billerica, MA, USA), an international life science research and diagnostics solutions provider, has entered into separate agreements to acquire ELITechGroup (Puteaux, France), a global manufacturer of in-vitro diagnostics (IVD), and Phasefocus Holdings Limited (Sheffield, UK), a cell imaging company. The acquisitions are expected to strengthen Bruker’s position in molecular diagnostics and microscopy, respectively.

According to a Dec. 26 regulatory filing, Bruker will acquire ELITech for a purchase price derived from an enterprise value of USD 966.1 million, subject to certain adjustments. ELITech has been owned and operated by private equity firm PAI Partners (Paris, France) since 2017. ELITech specializes in developing and manufacturing IVD instruments and reagents and enjoys a strong market position in niche IVD segments in molecular diagnostics and microbiology. The company offers products to hospitals and laboratories for diagnosing diseases, identifying disease risk factors, and optimizing treatment choices. ELITech has undertaken transformative initiatives, such as R&D investments, the launch of next-generation molecular diagnostics systems, and new strategic partnerships for product development. These initiatives have strengthened ELITech’s competitive position and improved its reputation as an industry innovator, resulting in significant financial growth and profitability.

“Our partnership with PAI, together with the hard work and drive for innovation of our teams, have helped develop ELITech into the company that it is today,” said Christoph Gauer, CEO of ELITech Group. “It’s incredibly rewarding to see that our collective efforts have been a success and position us well for this exciting next chapter. I’d like to thank PAI for their support over the years and look forward to what the ELITech team can achieve as part of Bruker.”

In a separate transaction, Bruker has signed a definitive agreement to acquire Phasefocus, a privately held company with leading expertise in imaging and image processing algorithms. Financial details of the transaction were not disclosed. Phasefocus has developed a novel optical microscope, called Livecyte, for label-free imaging that is based on strong algorithms and patented technology. Phasefocus’ microscopy capabilities will enhance Bruker’s existing portfolio, enabling new research advances in a range of cell imaging applications while Bruker’s global reach will help build on Phasefocus’ success to date.

“Phasefocus has extensive image processing and algorithm expertise that they have nicely deployed in their Livecyte product,” said Dr. Frank Burgaezy, President AXS division. “This is a good addition to our broad imaging portfolio and their technology will enable us to drive further product developments.”

“We are very pleased to join Bruker,” added Dr. Martin Humphry, CEO of Phasefocus. “Joining forces with a leading life-science tools provider with broad geographic reach enables us to give many more researchers access to our products for investigation of dynamic single cell behavior.”

Related Links:

Bruker Corporation
ELITechGroup
PAI Partners
Phasefocus Holdings Limited 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Signs of multiple sclerosis show up in blood years before symptoms appear (Photo courtesy of vitstudio/Shutterstock)

Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset

Autoimmune diseases such as multiple sclerosis (MS) are thought to occur partly due to unusual immune responses to common infections. Early MS symptoms, including dizziness, spasms, and fatigue, often... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: A new study has identified patterns that predict ovarian cancer relapse (Photo courtesy of Cedars-Sinai)

Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse

High-grade serous ovarian carcinoma is the most lethal type of ovarian cancer, and it poses significant detection challenges. Typically, patients initially respond to surgery and chemotherapy, but the... Read more